サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1542790

クローン病（CD）治療の世界市場

Crohn's Disease (CD) Therapy

出版日
ページ情報
英文 142 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
クローン病（CD）治療の世界市場
出版日: 2024年08月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 142 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

クローン病（CD）治療の世界市場は2030年までに177億米ドルに達する見込み

2023年に127億米ドルと推定されるクローン病（CD）治療の世界市場は、2023～2030年の分析期間においてCAGR 4.8%で成長し、2030年には177億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗TNF生物製剤は、CAGR 5.8%を記録し、分析期間終了時には74億米ドルに達すると予想されます。アミノサリチル酸塩セグメントの成長率は、分析期間中CAGR 2.8%と推定されます。

米国市場は35億米ドルと推定され、中国はCAGR 4.5％で成長すると予測される

米国のクローン病（CD）治療市場は2023年に35億米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR4.5%で推移し、2030年には28億米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.8％と3.7％と予測されています。欧州では、ドイツがCAGR約3.8％で成長すると予測されています。

クローン病（CD）治療の世界市場：主要動向と促進要因のまとめ

クローン病との闘い：クローン病治療の最新動向

クローン病（CD）治療は大きく進化しており、従来の対症療法から、疾患の経過を修正し、生活の質を改善することを目的とした、より的を絞ったアプローチへと移行しています。医学研究の進歩により、炎症に関与するタンパク質や経路を特異的に標的とする生物学的治療薬が開発されました。これにはTNF阻害剤、インテグリン阻害剤、インターロイキン阻害剤などがあり、多くの患者で症状の軽減と寛解の達成に効果を示しています。さらに、免疫調節薬と生物学的製剤の併用は、治療成績を高め、副作用を最小限に抑えるための一般的な戦略となっています。

新しい治療法はCDの治療パラダイムをどのように変えるのか？

CDの新たな治療法は、本疾患の発症に重要な役割を果たす免疫系と腸内細菌叢の新たなターゲットに焦点を当てています。JAK阻害剤は低分子の新しい薬剤で、炎症プロセスに関与する主要な酵素を阻害することにより、中等症から重症のCDの治療に有望視されています。さらに、糞便微生物叢移植（FMT）とプロバイオティクスの使用は、腸内細菌叢のバランスを回復するために研究されており、より良い疾患管理と寛解率につながる可能性のある治療への新しいアプローチを提供しています。

クローン病の管理にはどのような課題があるのか？

進歩にもかかわらず、クローン病の管理は、その複雑な性質と、患者によって症状や治療反応にばらつきがあることから、依然として困難です。最大の課題のひとつは、慢性再発寛解型であることで、長期的な管理戦略を複雑にし、患者の治療アドヒアランスに影響を及ぼす可能性があります。さらに、狭窄、瘻孔、大腸がんなどの合併症のリスクは、継続的なモニタリングや時には外科的介入を必要とし、疾患の負担を増大させる。さらに、新しい治療法、特に生物学的製剤のコストは法外に高く、多くの患者のアクセスを制限しています。

CD療法市場の成長を促すものは何か？

CD療法市場の成長は、いくつかの要因によってもたらされます。世界の炎症性腸疾患の罹患率の増加とCDに対する認知度の向上は、効果的な治療に対する需要の拡大に寄与する主要因です。診断技術の進歩により、より早期かつ正確な診断が可能となり、タイムリーな治療開始が促進されます。また、有効性と安全性を向上させた新規治療薬の開発も、市場の拡大を後押ししています。さらに、特に発展途上国における医療費の増加や医療インフラの整備は、先進的な治療法へのアクセスを向上させ、市場の成長をさらに後押ししています。

注目の競合企業（全46社）

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Celltrion Healthcare Co., Ltd.
  • ChemoCentryx, Inc.
  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP11374

Global Crohn's Disease (CD) Therapy Market to Reach US$17.7 Billion by 2030

The global market for Crohn's Disease (CD) Therapy estimated at US$12.7 Billion in the year 2023, is expected to reach US$17.7 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. Anti-TNF Biologics, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$7.4 Billion by the end of the analysis period. Growth in the Aminosalicyates segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 4.5% CAGR

The Crohn's Disease (CD) Therapy market in the U.S. is estimated at US$3.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 4.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.8% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Crohn's Disease (CD) Therapy Market - Key Trends and Drivers Summarized

Combating Crohn's Disease: What's New in CD Therapy?

Crohn's Disease (CD) therapy has evolved significantly, moving beyond traditional symptom management to more targeted approaches aimed at modifying the disease course and improving quality of life. Advances in medical research have led to the development of biologic therapies that specifically target proteins and pathways involved in inflammation. These include TNF inhibitors, integrin inhibitors, and interleukin inhibitors, which have shown efficacy in reducing symptoms and achieving remission in many patients. Additionally, the use of immunomodulators in combination with biologics has become a common strategy to enhance therapeutic outcomes and minimize side effects.

How Are Emerging Therapies Transforming Treatment Paradigms in CD?

Emerging therapies in CD focus on new targets within the immune system and the gut microbiome, which play crucial roles in the pathogenesis of the disease. JAK inhibitors, a newer class of small molecule drugs, have shown promise in treating moderate to severe CD by blocking key enzymes involved in the inflammatory process. Moreover, fecal microbiota transplantation (FMT) and the use of probiotics are being explored to restore intestinal microbiome balance, offering a novel approach to therapy that could potentially lead to better disease management and remission rates.

What Challenges Persist in the Management of Crohn's Disease?

Despite advancements, managing CD remains challenging due to its complex nature and variability in symptoms and treatment responses among patients. One of the biggest challenges is the chronic relapsing-remitting pattern of the disease, which can complicate long-term management strategies and affect patient adherence to treatment. Additionally, the risk of complications such as strictures, fistulas, and colorectal cancer requires ongoing monitoring and sometimes surgical intervention, adding to the disease burden. Furthermore, the cost of newer therapies, particularly biologics, can be prohibitively high, limiting access for many patients.

What Drives the Growth in the CD Therapy Market?

The growth in the CD therapy market is driven by several factors. An increasing incidence of inflammatory bowel diseases globally and greater awareness of CD are key factors contributing to the growing demand for effective treatments. Advances in diagnostic techniques allow for earlier and more accurate diagnosis, facilitating timely treatment initiation. The development of novel therapeutics that offer improved efficacy and safety profiles also stimulates market expansion. Additionally, rising healthcare expenditure and better healthcare infrastructure, particularly in developing countries, enhance access to advanced therapies, further driving market growth.

Select Competitors (Total 46 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Celltrion Healthcare Co., Ltd.
  • ChemoCentryx, Inc.
  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Crohn's Disease (CD) Therapy - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Crohn's Disease Drives Demand for Effective Therapies
    • Growing Awareness and Better Diagnostic Techniques Bolster Early Treatment Adoption
    • Expansion of Healthcare Infrastructure Supports Accessibility to Advanced CD Therapies
    • Emerging Markets Exhibit Increased Demand Due to Rising Healthcare Spending
    • Growing Demand for Non-Surgical Interventions Bolsters Non-Invasive Therapy Development
    • Shift Toward Combination Therapies Offers Comprehensive Disease Management
    • Nutritional Research Influences Adjunct Therapies in CD Treatment Regimens
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Crohn's Disease (CD) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Crohn's Disease (CD) Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Aminosalicyates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Aminosalicyates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Aminosalicyates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Immunomodulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Anti-TNF Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Anti-TNF Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Anti-TNF Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Anti-Integrin Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Anti-Integrin Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Anti-Integrin Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Crohn's Disease (CD) Therapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • JAPAN
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • CHINA
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: China 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • EUROPE
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Crohn's Disease (CD) Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Crohn's Disease (CD) Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • FRANCE
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: France 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • GERMANY
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: UK 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 59: Rest of World Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Rest of World Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Rest of World 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030

IV. COMPETITION